Dosing guidance for intravenous colistin in critically-ill patients.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background.: Intravenous colistin is difficult to use because plasma concentrations for antibacterial effect overlap those causing nephrotoxicity, and there is large interpatient variability in pharmacokinetics. The aim was to develop dosing algorithms for achievement of a clinically desirable average steady-state plasma colistin concentration (Css,avg) of 2 mg/L. Methods.: Plasma concentration-time data from 214 adult critically ill patients (creatinine clearance, 0–236 mL/min; 29 receiving renal replacement therapy [RRT]) were subjected to population pharmacokinetic analysis. Development of an algorithm for patients not receiving RRT was based on the relationship between the dose of colistimethate that would be needed to achieve a desired Css,avg and creatinine clearance. The increase in colistin clearance when patients were receiving RRT was determined from the population analysis and guided the supplemental dosing needed. To balance potential antibacterial benefit against risk of nephrotoxicity the algorithms were designed to achieve target attainment rates of >80% for Css,avg ≥2 and <30% for Css,avg ≥4 mg/L. Results.: When algorithm doses were applied back to individual patients not receiving RRT (including those prescribed intermittent dialysis on a nondialysis day), >80% of patients with creatinine clearance <80 mL/min achieved Css,avg ≥2 mg/L, but for patients with creatinine clearance ≥80 mL/min, the target attainment was <40%, even with the maximum allowed daily dose of 360 mg colistin base activity. For patients receiving RRT, target attainment rates were >80% with the proposed supplemental dosing. In all categories of patients, <30% of patients attained Css,avg ≥4 mg/L. Conclusions.: The project has generated clinician-friendly dosing algorithms and pointed to circumstances in which intravenous monotherapy may be inadequate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Self-citationGaronzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
Self-citationSandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., Behle, T. F., Bordinhão, R. C., Wang, J., Forrest, A., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit334 · Cited by 430
Self-citationColistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa
Bergen, P. J., Li, J., Rayner, C. R., & Nation, R. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00035-06 · Cited by 366
Self-citationPogue, J. M., Lee, J., Marchaim, D., Yee, V., Zhao, J. J., Chopra, T., Lephart, P., & Kaye, K. S. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir611 · Cited by 327
Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?
Nation, R. L., Velkov, T., & Li, J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu213 · Cited by 310
Self-citationSorlí, L., Luque, S., Grau, S., Berenguer, N., Segura, C., Montero, M. M., Álvarez-Lerma, F., Knobel, H., Benito, N., & Horcajada, J. P. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-380 · Cited by 225
Cheah, S.-E., Wang, J., Nguyen, V. T. T., Turnidge, J. D., Li, J., & Nation, R. L. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv267 · Cited by 206
Self-citationUpdated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
Nation, R. L., Garonzik, S. M., Li, J., Thamlikitkul, V., Giamarellos-Bourboulis, E. J., Paterson, D. L., Turnidge, J. D., Forrest, A., & Silveira, F. P. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ964 · Cited by 168
Self-citation
Research works printed but not linked: 2
- Forrest, Toxicodynamics for colistin-associated changes in creatinine clearance. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; 5–9 September 2014
- European Medicines Agency, Annex III: amendments to relevant sections of the summary of product characteristics and the package leaflets
Cited by
Items 101–200 of 273
A 10-year single-center experience on Stenotrophomonas maltophilia resistotyping in Szeged, Hungary
Gajdács, M., & Urbán, E. Z. (2020) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2020.00006 · Cited by 21
Xiang, W., Clemenza, P., Klousnitzer, J., Chen, J., Qin, W., Tristram‐Nagle, S., Doi, Y., Di, Y. P., & Deslouches, B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.889791 · Cited by 21
Pudpong, K., Pattharachayakul, S., Santimaleeworagun, W., Nwabor, O. F., Laohaprertthisan, V., Hortiwakul, T., Charernmak, B., & Chusri, S. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s363588 · Cited by 21
Leuppi-Taegtmeyer, A. B., Decosterd, L. A., Osthoff, M. F., Mueller, N. J., Buclin, T., & Corti, N. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01957-18 · Cited by 21
Chusri, S., Singkhamanan, K., Wanitsuwan, W., Suphasynth, Y., Kositpantawong, N., Kanchanasuwan, S., & Doi, Y. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.03.017 · Cited by 21
Antachopoulos, C., Geladari, A., Landersdorfer, C. B., Volakli, E., Ilia, S., Gikas, E. E., Gika, H., Σδούγκα, Μ., Nation, R. L., & Roilides, E. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00002-21 · Cited by 21
Self-citationWang, Y., Li, H., Xie, X., Wu, X., Li, X., Zhao, Z., Luo, S., Wan, Z., Liu, J., Fu, L., et al. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.09.013 · Cited by 21
Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic Fibrosis
Crass, R. L., Naimi, T. A., Wen, B., Souza, E., Murray, S., Pai, M. P., & Jia, S. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00792-21 · Cited by 20
Bassetti, M., Peghin, M., Mesini, A., & Castagnola, E. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s209264 · Cited by 21
Wang, S., Yang, K., Sheu, C., Chen, W.-C., Chan, M.-C., Feng, J., Chen, C.-M., Wu, B., Zheng, Z.-R., Chou, Y., et al. (2022) · Critical Care · doi:10.1186/s13054-022-03947-9 · Cited by 19
Zhao, M., Wu, X., Fan, Y., Zhang, Y., Guo, B., Yu, J., Cao, G.-Y., Chen, Y., Wu, J., Shi, Y., et al. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.12.025 · Cited by 19
Self-citationSchmidt, J. J., Strunk, A.-K., David, S., Bode‐Böger, S. M., Martens‐Lobenhoffer, J., Knitsch, W., Scherneck, S., Welte, T., & Kielstein, J. T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky511 · Cited by 19
Karvouniaris, M., Poulakou, G., Tsiakos, K., Chatzimichail, M., Papamichalis, P. A., Katsiaflaka, A., Oikonomou, K., Katsioulis, A., Palli, E., & Komnos, A. (2022) · Antibiotics · doi:10.3390/antibiotics11030405 · Cited by 18
Sadyrbaeva-Dolgova, S., García-Fumero, R., Ruíz, M. E., Pasquau-Liaño, J., Jiménez-Morales, A., & Hidalgo-Tenorio, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-19626-2 · Cited by 18
Chua, H. C., Tse, A. H. W., Smith, N. M., Mergenhagen, K. A., Cha, R., & Tsuji, B. T. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106269 · Cited by 20
Park, J., Yang, K., Chung, Y., Lee, K.-B., Kim, J.-Y., Kim, S.-B., Sohn, J. W., & Yoon, Y.-K. (2021) · Antibiotics · doi:10.3390/antibiotics10080903 · Cited by 16
Inwardly rectifying potassium channels mediate polymyxin-induced nephrotoxicity
Lü, J., Azad, M. A. K., Moreau, J. L. M., Zhu, Y., Jiang, X., Tonta, M. A., Lam, R., Wickremasinghe, H., Zhao, J., Wang, J., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04316-z · Cited by 16
Self-citationBarco, S., Castagnola, E., Mesini, A., Tripodi, G., & Cangemi, G. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.03.023 · Cited by 16
Bibliometric and visual analysis of nephrotoxicity research worldwide
He, T., Ao, J., Duan, C., Yan, R., Li, X., Liu, L., Zhang, J., & Li, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.940791 · Cited by 19
Reviving Polymyxins: Achievements, Lessons and the Road Ahead
Li, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-16373-0_1 · Cited by 15
Self-citationNulsopapon, P., Pongchaidecha, M., Nasomsong, W., Polwichai, P., Suphankong, S., Sirichote, P., Chaisomboonpan, S., & Santimaleeworagun, W. (2022) · Antibiotics · doi:10.3390/antibiotics11030355 · Cited by 14
Li, J., Coulthard, K. P., & Nation, R. L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-16373-0_10 · Cited by 14
Self-citationRam, K., Sheikh, S., Bhati, R. K., Tripathi, C. D., Suri, J. C., & Meshram, G. G. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13482 · Cited by 14
Dose optimisation of antibiotics used for meningitis
Heffernan, A. J., & Roberts, J. A. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000783 · Cited by 15
Bian, X., Liu, X., Hu, F., Feng, M., Chen, Y., Bergen, P. J., Li, J., Li, X., Guo, Y. P., & Zhang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.785893 · Cited by 14
Self-citationSistanizad, M., Hassanpour, R., & Pourheidar, E. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/1867674 · Cited by 14
Luterbach, C., Qiu, H., Hanafin, P. O., Sharma, R., Piscitelli, J. A., Lin, F., Ilomäki, J., Cober, E., Salata, R. A., Kalayjian, R. C., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00591-22 · Cited by 14
Self-citationWacharachaisurapol, N., Phasomsap, C., Sukkummee, W., Phaisal, W., Chanakul, A., Wittayalertpanya, S., Chariyavilaskul, P., & Puthanakit, T. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105940 · Cited by 14
Zhang, J., Song, C., Wu, M., Yue, J., Zhu, S., Zhu, P., Oo, C., Schlender, J., Lv, Z., Zhu, Y., et al. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106443 · Cited by 13
Ungthammakhun, C., Vasikasin, V., Simsiriporn, W., Juntanawiwat, P., & Changpradub, D. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107267 · Cited by 13
Bouchène, S., Marchand, S., Couet, W. R., Friberg, L. E., Gobin, P., Lamarche, I., Grégoire, N., Björkman, S. E., & Karlsson, M. O. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13026 · Cited by 13
Colistin Use in Patients with Chronic Kidney Disease: Are We Underdosing Patients?
Sorlí, L., Luque, S., Li, J., Rodríguez, E., Campillo, N., Fernández-Sala, X., Soldado‐Folgado, J., Domingo, I. A., Montero, M., Grau, S., et al. (2019) · Molecules · doi:10.3390/molecules24030530 · Cited by 13
Self-citationFan, Y., Li, Y., Chen, Y., Yu, J., Liu, X., Li, W., Guo, B., Li, X., Wang, J., Wu, H., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11060798 · Cited by 13
Ungthammakhun, C., Vasikasin, V., & Changpradub, D. (2022) · Antibiotics · doi:10.3390/antibiotics11081112 · Cited by 13
Qiao, L., Zuo, W., Yang, Y., Liu, X., Wang, Q., Yu, J., Jiayu, W., Xu, T., Jiang, J., Zhang, B., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106880 · Cited by 13
Sulaiman, H., Abdul-Aziz, M. H., & Roberts, J. A. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1602716 · Cited by 13
Actualización acerca de colistina (polimixina E): aspectos clínicos, PK/PD y equivalencias
Medina, J. (2017) · doi:10.29193/rmu.33.3.5 · Cited by 13
Dose Suggestions for Intravenous Colistin in Pediatric Patients: Caution Required
Nation, R. L. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix1048 · Cited by 13
Self-citationLin, Y., Aye, S. M., Rao, G. G., Zhou, Q. T., Chan, H., & Li, J. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106199 · Cited by 12
Self-citationOpportunities to enhance antibiotic stewardship: colistin use and outcomes in a low-resource setting
Moolla, M. S., Whitelaw, A. C., Decloedt, E. H., Koegelenberg, C. F. N., & Parker, A. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab169 · Cited by 12
Sangthawan, P., Geater, A. F., Naorungroj, S., Nikomrat, P., Nwabor, O. F., & Chusri, S. (2021) · Antibiotics · doi:10.3390/antibiotics11010002 · Cited by 12
Jitaree, K., Sathirakul, K., Houngsaitong, J., Asuphon, O., Saelim, W., Thamlikitkul, V., & Montakantikul, P. (2019) · Antibiotics · doi:10.3390/antibiotics8030125 · Cited by 11
Self-citationMessina, A. P., Brink, A. J., Richards, G. A., & van Vuuren, S. F. (2017) · South African Medical Journal · doi:10.7196/samj.2017.v108i1.12561 · Cited by 11
Clinical use of the polymyxins: the tale of the fox and the cat
Wenzler, E., Bunnell, K. L., & Danziger, L. H. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.12.023 · Cited by 11
Optimal control for colistin dosage selection
Gontijo, A. V. L., & Cavalieri, A. V. G. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09769-6 · Cited by 11
Dosing Colistin Properly: Let’s Save “Our Last Resort Old Drug!”
Corona, A., & Cattaneo, D. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix388 · Cited by 11
Sasal, W., Gmiter, D., & Kaca, W. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11368-4 · Cited by 10
An update on polymyxin susceptibility testing methods forAcinetobacter baumannii
Dafopoulou, K., Vourli, S., Tsakris, A., & Pournaras, S. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2019.1667230 · Cited by 10
Jean, S., Liu, C., Huang, T., Lai, C.-C., Liu, I.-M., Hsieh, P.-C., & Hsueh, P. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2412637 · Cited by 11
Expert Consensus on Polymyxin Antimicrobial Susceptibility Testing and Clinical Interpretation
Yang, Q., Ma, X., Hu, F., Zhang, J., Sun, T., Chen, B., Xu, Y., & Liu, Y. (2021) · Chinese Medical Sciences Journal · doi:10.24920/003864 · Cited by 10
Wacharachaisurapol, N., Sukkummee, W., Anunsittichai, O., Srisan, P., Sangkhamal, S., Chantharit, P., Vandepitte, W. P., Wattanavijitkul, T., & Puthanakit, T. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.06.052 · Cited by 10
Analytical methodologies for measuring colistin levels in pharmacokinetic studies
Zabidi, M. S., Bakar, R. A., Musa, N., & Yusuf, W. N. W. (2020) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2020.1783291 · Cited by 10
Giacobbe, D. R., Karaiskos, I., & Bassetti, M. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1961743 · Cited by 10
Huang, X., Liu, X., Fan, Y., Wang, Y., Guo, B., Wang, J., Yu, J., Wei, Q., Wu, X., Huang, H., et al. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107326 · Cited by 9
Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study
Oberrauch, S., Lü, J., Cornthwaite‐Duncan, L., Hussein, M. H., Li, J., Rao, G. G., & Velkov, T. (2022) · Journal of Visualized Experiments · doi:10.3791/63540 · Cited by 9
Self-citationLam, S. W., & Athans, V. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00531-19 · Cited by 9
Angles-Yanqui, E., Chumbes-Pérez, J., & Huaringa-Marcelo, J. (2020) · Infectio · doi:10.22354/in.v24i4.876 · Cited by 9
Xü, Y., Liang, P., Liu, N., Dong, D., Gu, Q., & Wang, X. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1010 · Cited by 9
Suk, P., Rychlíčková, J., Součková, L., Kubíčková, V., & Urbánek, K. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-071649 · Cited by 9
Gómez‐Junyent, J., Rigo-Bonnin, R. F., Benavent, E., Soldevila, L., Padullés, A., Cabo, X., Tubau, F., Ariza, J., & Murillo, Ó. (2020) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-020-00625-5 · Cited by 9
A retrospective review of colistin utilisation at a tertiary care academic hospital in South Africa
Majavie, L., Johnston, D., & Messina, A. P. (2021) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v36i1.205 · Cited by 9
Cai, X., Chen, Y., Fu, J., Chen, Y., Shi, L., Chen, C., Zhang, C., Zhou, S., Zhou, W., Wu, B., et al. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107346 · Cited by 8
Liu, C., Leng, B., Xie, M., Jiang, S., Guan, X., Xu, J., Guo, Y., Jiang, J., & Zeng, J. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107418 · Cited by 8
Shyam, M., Pal, A., Dey, D., Kiruba, J., Sharma, V., Wadhwa, J., Srirangan, P., & Prince, S. E. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70649 · Cited by 9
Individualized optimization of colistin loading doses
Gontijo, A. V. L., & Cavalieri, A. V. G. (2022) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-022-09831-x · Cited by 8
Polymyxin Susceptibility Testing and Breakpoint Setting
Turnidge, J. D., Sei, K., & Mouton, J. W. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-16373-0_9 · Cited by 8
Talizin, T. B., Carrilho, C. M. D. D. M., Grion, C. M. C., Cardoso, L. T. Q., Tanita, M. T., Boll, K. M., Kauss, I. A. M., Festti, J., Lopes, C. R., da Silva, L. M. A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237880 · Cited by 8
Investigation of unbound colistin A and B in clinical samples using a mass spectrometry method
Fage, D., Deprez, G., Wolff, F. C., Hites, M., Jacobs, F., Françoise Van Bambeke, A., & COTTON, F. J. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.10.017 · Cited by 8
PASCALE, G. D., Lisi, L., Cutuli, S. L., Marinozzi, C., Palladini, A., Sancho, E., Tanzarella, E. S., Lombardi, G., Grieco, D. L., Caroli, A., et al. (2024) · Annals of Intensive Care · doi:10.1186/s13613-024-01384-1 · Cited by 7
Lee, J., Lee, I., Lee, K.-B., & Lee, S. S. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01880-24 · Cited by 7
Kyriazopoulou, E., & Giamarellos‐Bourboulis, E. J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1589451 · Cited by 7
Self-citationReview of the international consensus guidelines for the optimal use of the polymyxins
Елисеева, Е. В., Azyzov, I. S., & Zubareva, N. (2019) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2019.4.282-309 · Cited by 7
Yu, X., Pan, J., Zhou, Z., Wen, X., Dai, Y., Lin, G., Jiao, Z., & Zhang, C. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03945-1 · Cited by 7
Grewal, A., Thabet, P., Dubinsky, S., Purkayastha, D., Wong, K., Marko, R., Hiremath, S. S., Hutton, B., & Kanji, S. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2861 · Cited by 7
A fluorescent artificial receptor with specific imprinted cavities to selectively detect colistin
Turan, E., & Zengin, A. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-02873-5 · Cited by 7
Jeong, Y., Gu, N., Kwack, W. G., Kang, Y.-S., Park, S. Y., & Yoon, Y.-S. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.10.017 · Cited by 7
El desafio en la dosificación de colistin: actualización de las recomendaciones disponibles
Rosales, R., Rojas, L., Zamora, F. X., Giannina Izquierdo, C., Benavides, C., & González, C. D. (2018) · Revista chilena de infectología · doi:10.4067/s0716-10182018000200105 · Cited by 7
Narayanasamy, S., Nation, R. L., Mahony, A. A., Grayson, M. L., Kwong, J. C., Sherry, N. L., Khumra, S., Ellis, A. G., Frauman, A. G., & Holmes, N. E. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa572 · Cited by 7
Self-citationBoonyasiri, A., Fuhs, D. T., Naorungroj, T., Wang, L., Wang, J., Ratanarat, R., Li, J., Nation, R. L., Thamlikitkul, V., & Landersdorfer, C. B. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.05.021 · Cited by 6
Self-citationHussein, M. H., Oberrauch, S., Allobawi, R., Cornthwaite‐Duncan, L., Lü, J., Sharma, R., Baker, M. A., Li, J., Rao, G. G., & Velkov, T. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.10.041 · Cited by 6
Self-citationColistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: De Novo or Drug Exposure?
Maćešić, N., Nelson, B. C., & Uhlemann, A. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix393 · Cited by 6
Biswal, D., Chawla, A., Kumari, P., Mangla, S., & Salhotra, R. (2025) · Journal of Critical Care · doi:10.1016/j.jcrc.2025.155207 · Cited by 5
A novel role for colistin as an efflux pump inhibitor in multidrug-resistant Klebsiella pneumoniae
Sharma, R., Yeshwante, S., Bui, N. M., Carbone, V., Hicks, L. M., Blough, B. E., Velkov, T., & Rao, G. G. (2025) · Scientific Reports · doi:10.1038/s41598-025-18206-4 · Cited by 5
Pulakat, L., Chen, H. H., Gavini, M. P., Ling, L. A., Tang, Y., Mehm, A., Martin, G., Beale, C., Mooney, B., & Sun, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050976 · Cited by 5
Unravelling the Hepatic Elimination Mechanisms of Colistin
Qi, B., Gijsen, M., Vocht, T. D., Deferm, N., Brantegem, P. V., Abza, G. B., Nauwelaerts, N., Wauters, J., Spriet, I., & Annaert, P. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03536-7 · Cited by 5
Smith, N. M., Boissonneault, K. R., Holden, P. N., Kaur, J. N., Klem, J. F., Cha, R., Sutton, M. D., & Tsuji, B. T. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107260 · Cited by 5
Pharmacokinetic Changes and Influencing Factors of Polymyxin B in Different ECMO Modes
Xu, M., Chen, N., Yu, Y., Pan, X.-Y., & Li, T. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s486169 · Cited by 5
Jeon, C.-H., Kim, S., Kim, H., Park, K., & Wi, Y. M. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.03.007 · Cited by 5
Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects
Li, S., Zhu, X., Cao, G., Shen, J., Zhu, X., Yu, J., Wu, X., Wu, J., Yang, H., Li, N., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01563-23 · Cited by 5
Chin, M. K. Y., Hsia, Y., Goossens, H., Versporten, A., Bielicki, J. A., Sharland, M., & Donà, D. (2020) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002847 · Cited by 5
Hua, X., Li, C., Pogue, J. M., Sharma, V., Karaiskos, I., Kaye, K. S., Tsuji, B. T., Bergen, P. J., Zhu, Y., Song, J., et al. (2020) · JMIR mhealth and uhealth · doi:10.2196/20525 · Cited by 5
Self-citationNguyen, V. T. K., Montakantikul, P., Tragulpiankit, P., Houngsaitong, J., & Shuib, M. F. (2021) · Antibiotics · doi:10.3390/antibiotics10050595 · Cited by 5
The Optimal Use of the Polymyxins Before Their Time Is Up
Alosaimy, S., Jorgensen, S. C. J., & Rybak, M. J. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2207 · Cited by 5
Population pharmacokinetics of colistin sulfate in critically ill patients based on NONMEM
Sun, Q., Li, X., Wang, G., Wang, X., Xing, B., Xun, Z., Lu, N., & Li, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-03503-9 · Cited by 4
Zhao, T., Liu, L., Yang, G., Yu, H., Qiu, L., Li, X., Xiang, D., & Gong, X. (2025) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2025.05.001 · Cited by 4
Albayrak, A., Özger, H. S., Başgut, B., Aygencel, G., & Karahalıl, B. (2023) · Journal of Chemotherapy · doi:10.1080/1120009x.2023.2196916 · Cited by 5
Soman, R. N., Veeraraghavan, B., Hegde, A. V., Varma, S., Todi, S. K., Singh, R. K., Nagavekar, V., Rodrigues, C. S., Swaminathan, S., Ramsubramanian, V., et al. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2360116 · Cited by 4
Antimicrobial Therapy for Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria
Wi, Y. M., & Kang, C. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.5.439 · Cited by 4
Wacharachaisurapol, N., Kawichai, S., Chanakul, A., & Puthanakit, T. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.03.059 · Cited by 4
Guo, C., Lin, X., Qu, X., Huang, Z., Li, S., Li, W., Liu, X., & Zhang, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-96407-7 · Cited by 3
Metadata
- Authors
- Nation, R. L., Garonzik, S. M., Thamlikitkul, V., Giamarellos-Bourboulis, E. J., Forrest, A., Paterson, D. L., Li, J., & Silveira, F. P.
- Affiliations
- Monash University (AU)
- School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo 3 ;
- Siriraj Hospital (TH)
- Fourth Department of Internal Medicine, University of Athens 6 Medical School ,
- University at Buffalo, State University of New York (US)
- The University of Queensland (AU)
- University of Pittsburgh Medical Center (US)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-12-23
- Volume
- 64
- Issue
- 5
- Pages
- 565-571
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC5850520
- OpenAlex
- W2566638444
- Cited by
- 262
- References
- 27
- Citations by year
- 2026: 13 · 2025: 21 · 2024: 18 · 2023: 17 · 2022: 31 · 2021: 27 · 2020: 42 · 2019: 42 · 2018: 27 · 2017: 23
- FWCI
- 24.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI070896)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- colistin, intravenous administration, dosing algorithm, critically ill patients, nephrotoxicity, population pharmacokinetics, creatinine clearance, renal replacement therapy, colistimethate, steady-state plasma concentration, antibiotic dosing
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Colistin, Female, Humans, Male, Middle Aged, Pilot Projects, Critical Illness, Practice Guidelines as Topic, Renal Replacement Therapy, Young Adult, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.